Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 113,193 shares of the biopharmaceutical company’s stock after acquiring an additional 151 shares during the period. DekaBank Deutsche Girozentrale owned 0.09% of Alnylam Pharmaceuticals worth $36,501,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at about $275,000. Strs Ohio purchased a new position in Alnylam Pharmaceuticals during the first quarter worth about $7,781,000. GAMMA Investing LLC raised its stake in shares of Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 77 shares during the period. Finally, Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $243,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.5%

ALNY stock opened at $474.00 on Wednesday. The stock has a market capitalization of $62.13 billion, a PE ratio of -191.90 and a beta of 0.36. The company has a fifty day moving average of $457.90 and a 200-day moving average of $356.04. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the business earned ($0.13) earnings per share. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the transaction, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the transaction, the executive vice president directly owned 20,221 shares of the company’s stock, valued at $9,129,377.08. This trade represents a 13.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock valued at $44,160,261 in the last three months. 1.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ALNY. Evercore ISI boosted their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research report on Thursday, September 11th. UBS Group lifted their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research report on Friday, August 1st. BMO Capital Markets increased their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Chardan Capital increased their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Finally, Jefferies Financial Group raised their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a “buy” rating in a research report on Monday, July 7th. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $466.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.